A noninvasive method for predicting clinically significant prostate cancer using magnetic resonance imaging combined with PRKY promoter methylation level: a machine learning study.

Authors:
Wang Y; Liu W; Chen Z; Zang Y; Xu L and 3 more

Journal:
BMC Med Imaging

Publication Year: 2024

DOI:
10.1186/s12880-024-01236-1

PMCID:
PMC10929135

PMID:
38468226

Journal Information

Full Title: BMC Med Imaging

Abbreviation: BMC Med Imaging

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Diagnostic Imaging

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

".Declarations Ethics approval and consent to participateAll experiments in this study was performed in accordance with relevant guidelines and regulations. This study was approved by the Ethics Committees of the Second Affiliated Hospital of Soochow University in 2022. The approval number is JDLK202205901. All the patients were informed about and provided consent for the study. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding This study is supported by grants for Jin Zhu from the Gusu Talent Program (No. GSWS2021016)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025